SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

ZATELLI, Maria Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.179
EU - Europa 5.011
AS - Asia 3.631
SA - Sud America 20
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
AF - Africa 4
Totale 25.862
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.120
CN - Cina 1.783
DE - Germania 1.360
UA - Ucraina 1.085
SG - Singapore 1.041
IT - Italia 892
TR - Turchia 612
GB - Regno Unito 490
FI - Finlandia 355
SE - Svezia 262
PL - Polonia 203
RU - Federazione Russa 156
ID - Indonesia 130
FR - Francia 56
CA - Canada 51
BE - Belgio 50
NL - Olanda 26
LT - Lituania 16
VN - Vietnam 16
BR - Brasile 12
CZ - Repubblica Ceca 10
EU - Europa 10
IN - India 9
HK - Hong Kong 8
IE - Irlanda 8
IR - Iran 8
DK - Danimarca 7
MX - Messico 7
JP - Giappone 6
RO - Romania 6
AU - Australia 5
CH - Svizzera 5
ES - Italia 5
KR - Corea 4
EC - Ecuador 3
GR - Grecia 3
HU - Ungheria 3
BG - Bulgaria 2
LV - Lettonia 2
NG - Nigeria 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PE - Perù 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
AR - Argentina 1
AT - Austria 1
BD - Bangladesh 1
CL - Cile 1
CY - Cipro 1
EG - Egitto 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
PA - Panama 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 25.862
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.085
Fairfield 1.882
Chandler 1.487
Ashburn 1.393
Jacksonville 1.264
Houston 1.195
Santa Clara 1.060
Singapore 854
Ann Arbor 842
Seattle 737
Wilmington 706
Cambridge 626
Izmir 409
Nanjing 374
Beijing 330
Princeton 311
Addison 276
Ferrara 233
Warsaw 203
San Diego 182
Boardman 179
Shanghai 171
Milan 168
Jakarta 130
New York 120
Shenyang 119
Helsinki 118
Nanchang 110
Los Angeles 101
Dearborn 100
Bremen 92
Hebei 85
Changsha 66
Tianjin 59
London 57
Mountain View 56
Jiaxing 55
Falls Church 52
Jinan 51
Washington 50
Brussels 44
Kunming 41
Redwood City 38
Munich 37
Norwalk 35
Frankfurt am Main 32
Bologna 31
Guangzhou 31
Tappahannock 29
Toronto 29
Orange 26
Ningbo 25
San Mateo 23
Auburn Hills 22
Des Moines 19
Indiana 19
Hangzhou 18
Zhengzhou 18
Falkenstein 17
Leawood 17
Rome 17
Taizhou 17
Dong Ket 16
Hefei 16
Chicago 12
Lanzhou 11
Ottawa 11
Redmond 11
Augusta 10
Modena 10
Padova 10
Changchun 9
Brno 7
Chengdu 7
Ferrara di Monte Baldo 7
Haikou 7
Hong Kong 7
Monmouth Junction 7
Ardabil 6
Lappeenranta 6
Naples 6
Philadelphia 6
Walnut 6
Yellow Springs 6
Council Bluffs 5
Dallas 5
Fort Worth 5
Kilburn 5
Mumbai 5
Prescot 5
Amsterdam 4
Ancona 4
Chiswick 4
Dublin 4
Fuzhou 4
Parma 4
San Francisco 4
Shijiazhuang 4
Siena 4
Southwark 4
Totale 19.237
Salva come PNG Salva come JPEG
Nome #
SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma 342
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 241
Igf-I influences everolimus activity in medullary thyroid carcinoma 171
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 169
Magmas Overexpression Inhibits Staurosporine Induced Apoptosis in Rat Pituitary Adenoma Cell Lines 165
Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses 165
Role of Ultrasonographic/Clinical Profile, Cytology, and BRAF V600E Mutation Evaluation in Thyroid Nodule Screening for Malignancy: A Prospective Study 160
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 158
Applicability of laparoscopic approach to the resection of large adrenal tumours: a retrospective cohort study on 200 patients 157
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism 156
Relevance of BRAF(V600E) Mutation Testing Versus RAS Point Mutations and RET/PTC Rearrangements Evaluation in the Diagnosis of Thyroid Cancer 151
Increase in Peripheral CD3-CD56brightCD16- Natural Killer Cells in Hashimoto's Thyroiditis Associated with HHV-6 Infection 150
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. 146
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. 145
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 144
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion. 143
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 143
Cyclin D1 levels are involved in the resistance to m-TOR inhibitors in human bronchial carcinoids 140
Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors 140
Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory 139
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 136
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 136
Involvement of PKCβ and PKCδ isoforms in TSH signaling pathway in thyroid cancer cell lines 135
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 135
X-linked acrogigantism syndrome: clinical profile and therapeutic responses 134
8th edition of the AJCC/TNM staging system of thyroid cancer: What to expect (ITCO#2) 131
Levels of p27 sensitize to dual PI3K/mTOR inhibition 130
Functional characterization of a new deletion in CDKN1B 5'-UTR region 130
The cytotoxic effect of sunitinib on human bronchial carcinoid cell lines and primary cultures is counteracted by EGF and IGF-1 but not by VEGF 130
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 129
VEGF autocrine secretion is enhanced by EGFR activation trough ERK1/2 phosphorylation in human adrenocortical carcinoma cell lines 127
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. 126
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 126
Pituitary side effects of old and new drugs. 126
Cerebral aneurysm and acromegaly: a case report 125
IGF-I Proliferative Effects Are Inhibited by Targeting PKC in Human Endocrine Tumor Cells 125
Epidermal growth factor pathway as a possible target in the medical therapy of bronchial carcinoids 124
Magmas, a Gene Newly Identified as Overexpressed in Human and Mouse ACTH-Secreting Pituitary Adenomas, Protects Pituitary Cells from Apoptotic Stimuli 123
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 123
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine needle aspiration biopsies. 123
Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: a prospective study on 345 patients with a 3-year follow-up. 121
HHV-6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis 121
Should aip gene screening be recommended in family members of FIPA patients with R16H variant? 121
Magmas, a Novel Over-Expressed Gene in Pituitary Rat Cell Lines and in Human Pituitary Adenomas: A New Pituitary Biomarker? 121
In vitro testing of new somatostatin analogs on pituitary tumor cells 120
mTOR, p70S6K, AKT and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 120
Rare diseases in clinical endocrinology: a taxonomic classification system. 120
The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. 120
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 120
Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma 119
Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto’s thyroiditis 119
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. 119
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. 118
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation 118
Growth hormone excess promotes breast cancer chemoresistance 118
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 118
mTOR mediated IGF1 proliferative effects on a rat pituitary GH/PRL secreting pituitary adenoma cell line 118
Runx2 mRNA Expression in the Tissue, Serum, and Circulating Non-Hematopoietic Cells of Patients with Thyroid Cancer 116
EGF and IGF1 affect sunitinib activity in BP-NEN: New putative targets beyond VEGFR? 116
Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. 115
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 115
null 114
Magmas, a novel over-expressed gene in Pituitary rat cell lines and in human pituitary adenomas: a new pituitary bio marker? 114
Evaluation of bone markers and structure in subclinical Cushing’s syndrome 114
Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. 114
miR-15a and miR-16-1 down-regulation in pituitary adenomas 114
null 113
Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells 113
MTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors 112
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH) 112
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 111
BRAFV600E analysis on fine needle aspiration biopsy increases diagnostic accuracy for papillary thyroid cancer in clinically unsuspected nodules 111
null 111
Effects of two mTOR inhibitors on in-vitro models of GH-secreting pituitary adenomas 111
Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame 111
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. 111
An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro 110
Utilization of luminescent technology to develop a kinase assay: Cdk4 as a model system 110
N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances staurosporine cytotoxic effects likely inhibiting the protective action of Magmas toward cell apoptosis 110
Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines 109
Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects 108
MicroRNAs and possible role in pituitary adenoma 107
Cushing in a Leaf: Endocrine Disruption From a Natural Remedy 107
null 106
Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. 106
Adrenal cavernous hemangioma: a case report 106
Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide 105
Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT 105
Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells 105
Inhibitory effect of dihydrotestosterone on human thyroid cell growth 105
Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review 105
Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression 105
Evaluation of the Role of BRAFV600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study 105
Presenza di HHV-6 in campioni tiroidei di pazienti con malattie autoimmuni della tiroide 104
Expression of functional KISS1 and KISS1R system is altered in human pituitary adenomas: evidence for apoptotic action of kisspeptin-10. 103
Response to Pitoia and Niepomniszcze Thyroid 103
Growth hormone induces chemoresistance in breast cancer cells 102
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study 102
null 101
Somatostatin receptors: from basic science to clinical approach - Thyroid. 101
Totale 12.608
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.315
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.299
Totale 141.614
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.707 0 0 0 0 0 614 421 481 358 498 255 80
2020/20213.348 271 234 199 449 206 341 101 368 98 477 429 175
2021/20222.754 113 256 179 54 118 160 129 151 114 223 266 991
2022/20233.186 321 277 130 435 467 440 168 266 385 26 165 106
2023/20242.076 151 193 103 57 138 315 56 454 58 47 49 455
2024/20252.878 206 165 605 202 929 771 0 0 0 0 0 0
Totale 26.359